Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel, Stable, and Well-Secreted Single-Chain Fc Forms of Programmed Death-1 Immune Checkpoint Inhibitor Efficiently Block PD-1/PD-L1 Interaction.

Human gene therapy·2026
Same author

The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized mice.

Gene therapy·2026
Same author

CGT 4.0: a distant dream or inevitable future? Smart process automation is critical to make efficient scalability of CGT manufacturing a reality.

Frontiers in bioengineering and biotechnology·2025
Same author

Insight Into the Degradation Pathways of an AAV9.

Journal of pharmaceutical sciences·2024
Same author

Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing.

Cytotherapy·2024
Same author

Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy.

Frontiers in medicine·2023

Related Experiment Video

Updated: Aug 15, 2025

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
07:21

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models

Published on: June 30, 2021

6.2K

Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy.

Reetta A E Eriksson1,2, Tiina Nieminen1, Lionel Galibert1

  • 1Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.

Frontiers in Medicine
|December 30, 2022
PubMed
Summary

Researchers developed a novel gene therapy method using tetracycline-inducible riboswitches for precise temporal control of therapeutic gene expression. This system offers dose-dependent, reversible gene regulation within hours, enhancing gene therapy applications.

Keywords:
AAV (adeno-associated virus)ON-switchVEGF-Bgene therapyriboswitchtetracyclinetransgene expression regulation

More Related Videos

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

36.7K
Production and Titering of Recombinant Adeno-associated Viral Vectors
08:35

Production and Titering of Recombinant Adeno-associated Viral Vectors

Published on: November 27, 2011

61.8K

Related Experiment Videos

Last Updated: Aug 15, 2025

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
07:21

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models

Published on: June 30, 2021

6.2K
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

36.7K
Production and Titering of Recombinant Adeno-associated Viral Vectors
08:35

Production and Titering of Recombinant Adeno-associated Viral Vectors

Published on: November 27, 2011

61.8K

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • RNA Therapeutics

Background:

  • Temporal regulation of gene expression is crucial for effective gene therapy.
  • Riboswitches are RNA elements that can control gene expression in response to small molecules.
  • Existing riboswitches require optimization for robust and controllable transgene expression.

Purpose of the Study:

  • To compare different tetracycline and toyocamycin-inducible ON-riboswitches for drug-responsive transgene expression.
  • To optimize riboswitch-controlled gene expression cassettes for enhanced therapeutic applications.
  • To evaluate the impact of expression cassette elements on riboswitch functionality.

Main Methods:

  • Screening of multiple tetracycline-dependent and toyocamycin-dependent ON-riboswitches.
  • Application of the best-performing riboswitch (K19) to various transgenes using plasmid and adeno-associated virus (AAV) vectors.
  • Optimization of gene expression cassettes using multiple riboswitches and linker sequences.
  • Assessment of gene expression induction, dose-dependency, reversibility, and kinetics.
  • Evaluation of promoter independence and the effect of WPRE elements.

Main Results:

  • The tetracycline-dependent K19 riboswitch demonstrated superior control over transgene expression.
  • Gene expression was induced 6- to 10-fold, showing dose-dependency and reversibility within hours.
  • Dual or triple riboswitches, particularly with a linker sequence, reduced leakiness and improved dynamic range.
  • Riboswitch function was independent of the promoter, but WPRE elements negatively impacted functionality.
  • An optimized dual riboswitch construct at the 3' end of the transgene with a linker was developed.

Conclusions:

  • The K19 riboswitch provides effective temporal control for gene therapy applications.
  • Optimized riboswitch expression cassettes significantly enhance dynamic range and reduce leakiness.
  • Understanding riboswitch function and expression cassette design is critical for advancing gene therapy.
  • This study provides a foundation for developing advanced riboswitch-based gene regulation systems.